This incidence was significantly higher compared to patients not on a GLP-1 RA, showing a strong link between GLP-1 RA drugs and potential aspiration risk under anesthesia. said author Sudipta Sen MD, anesthesiologist and associate professor, UTHealth in Houston
Review Treatment Options and Management Strategies Treatment for ischemic optic neuropathy is personalized, considering the specific type and underlying causes
Melanotan 1 has a half-life of approximately 1.5 hours when administered subcutaneously, so some researchers have administered the peptide twice daily to skin disorder patients to maintain therapeutic levels [17]
Working with a physician can help to minimize risks, monitor side effects and evaluate for efficacy. How can physicians address these issues
Serious selenium deficiency in the serum of patients with Kashin-Beck disease and the effect of nano-selenium on their chondrocytes
What we do in that scenario is keep patients at the lowest dose before escalating, to let their body adjust to the medication. While the low and slow method can work for many people, with side effects often leveling out over time, for some, they arent tolerable, even at the lowest starting dose
